On of mixed lineage kinase three is required for Neurofibromatosis-2-mediated expansion suppression in human most cancers. Oncogene. 2011 Feb 17; thirty(seven):78189. [PubMed: 20890305] forty eight. !!! INVALID Citation !!! 49. Lawrence TS, Blackstock AW, McGinn C. The system of action of radiosensitization of traditional chemotherapeutic brokers. Seminars in radiation oncology. 2003 Jan; 13(one):131. [PubMed: 12520460] 50. Park EJ, Chan DW, Park JH, Oettinger MA, Kwon J. DNA-PK is activated by nucleosomes and phosphorylates H2AX within the nucleosomes in an acetylation-dependent method. Nucleic acids exploration. 2003 Dec 1; 31(23):6819827. [PubMed: 14627815] fifty one. Stiff T, O’Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA. ATM and DNA-PK purpose redundantly to phosphorylate H2AX following exposure to ionizing radiation. Most cancers Res. 2004 Apr one; sixty four(7):2390396. [PubMed: 15059890] 52. Ward IM, Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational worry. J Biol Chem. 2001 Dec 21; 276(fifty one):477597762. [PubMed: 11673449]NIH-PA Author Manuscript NIH-PA Writer Manuscript NIH-PA Author ManuscriptNeurosurgery. Creator manuscript; available in PMC 2015 857402-63-2 Technical Information February 02.Yue et al.Page53. Ward IM, Minn K, Chen J. UV-induced ataxia-telangiectasia-mutated and Rad3-related (ATR) activation demands replication tension. J Biol Chem. 2004 Mar 12; 279(eleven):9677680. [PubMed: 14742437] 54. Fernandez-Capetillo O, Chen HT, Celeste A, et al. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Mother nature cell biology. 2002 Dec; 4(12):99397. fifty five. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. H2AX: the histone guardian from the genome. DNA repair. 2004 Aug-Sep;3(eight):95967. [PubMed: 15279782] 56. Lu C, Zhu F, Cho YY, et al. Cell apoptosis: requirement of H2AX in DNA ladder development, but not for that activation of caspase-3. Mol Mobile. 2006 Jul 7; 23(one):12132. [PubMed: 16818236] 57. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand crack repair pathway decision. Cell study. 2008 Jan; 18(1):13447. [PubMed: 18157161] 58. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, et al. Histone H2AX phosphorylation is dispensable with the preliminary recognition of DNA breaks. Mother nature mobile biology. 2003 Jul; five(7):67579. 59. Celeste A, Petersen S, Romanienko PJ, et al. Genomic instability in mice lacking histone H2AX. Science. 2002 May well three; 296(5569):92227. [PubMed: 11934988] sixty. Lee TX, Packer MD, Huang J, et al. Growth inhibitory and AGM-1470 MSDS anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. European journal of most cancers. 2009 Jun; forty five(9):1709720. [PubMed: 19359162] sixty one. James MF, Han S, Polizzano C, et al. NF2merlin is a novel PF-06747711 Solubility destructive regulator of mTOR advanced 1, and activation of mTORC1 is linked with meningioma and schwannoma progress. Mol Mobile Biol. 2009 Aug; 29(fifteen):4250261. [PubMed: 19451225] 62. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO. Dissecting and targeting the growth factor-dependent and advancement factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res. 2008 Jul 1; 68(thirteen):5236245. [PubMed: 18593924] sixty three. Subbiah V, Slopis J, Hong DS, et al. Remedy of people with sophisticated neurofibromatosis type two with novel molecularly focused therapies: from bench to bedside. Journal of medical oncology : formal journal in the American Culture of Scientific Oncology. 2012 Feb ten; 30(five):e64 68. [PubMed: 22203760] 64. Ammoun S, Cunliffe.
